COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series

Objective To assess the safety, immunogenicity and cellular responses following the Moderna Spikevax primary series in rheumatic disease.Methods We conducted a 12-month, prospective, non-randomised, open-label, comparative trial of adults with either rheumatoid arthritis (RA, n=131) on stable treatm...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Emmanouil Rampakakis, Paul R Fortin, Sasha Bernatsky, Louis Bessette, Ines Colmegna, Elizabeth Hazel, Laëtitia Michou, Mary-Ann Fitzcharles, Louis Flamand, Emmanuelle Rollet-Labelle, Marc-André Langlois, Valeria Valerio, Nathalie Amiable, Mariana Useche, Deirdre McCormack, Pantelis Panopalis
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMJ Publishing Group 2023-10-01
Edice:	RMD Open
On-line přístup:	https://rmdopen.bmj.com/content/9/4/e003400.full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!